ArticleCancer discovery2023
Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC.
Article in Cancer discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma.Cancer discovery · 2025Article
- Article
Corrections and comments
- Comment on
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In separate trials, the RET inhibitor selpercatinib showed superiority over standard of care in RET-mutated medullary thyroid cancer and in RET fusion-positive non-small cell lung cancer-although researchers say more follow-up is needed. The findings highlight the importance of tumor sequencing.
Indexed as
Identifiers
37874126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.